抗瘧疾藥市場:各類藥物，各給藥途徑，各流通管道，各地區-市場規模，佔有率，展望，機會分析，2023年～2030年

市場動態

正在進行的瘧疾治療研究和開發預計將推動預測期內市場的增長。各種藥物正在進行瘧疾治療的臨床試驗，預計這也將在預測期內推動市場。

本調查的主要特徵

• 本報告提供以2021年為基準年的預測期間（2022-2030 年）之全球抗瘧疾藥市場的市場規模和復合年增長率（CAGR %）相關的詳細分析。
• 並闡明不同部門市場的潛在收入機會，說明該市場具有魅力的投資主張矩陣。
• 同時並提供市場推動因素和限制、機會、新產品發布或批准、市場趨勢、區域前景和主要參與者採用的競爭戰略等重要考察。
• 並基於企業亮點，各類型投資組合、主要焦點、財務業績和市場策略等參數，介紹全球抗瘧疾藥市場的主要參與者之企業簡介。
• 藉由該報告提供的洞察，將能幫助營銷人員和公司高管能夠就未來的產品發布、類型升級、市場擴張和營銷策略做出明智的決策。
• 全球抗瘧疾藥市場報告配合該行業的各種利益相關者，包括投資者、供應商、產品製造商、分銷商、新進入者和金融分析師。
• 利益相關者可以透過全球抗瘧疾藥市場用於分析的各種戰略矩陣來幫助他們更容易做下決策。

目錄

第1章 調查目的與前提條件

• 調查目的
• 前提條件
• 簡稱

第2章 市場概況

• 報告概要
  • 市場定義和範圍
• 摘要整理

第3章 市場動態，法規，趨勢分析

• 市場動態
  • 促進因素
  • 阻礙因素
  • 市場機會
• 影響分析
• 最近的產品上市
• 流行病學
• 合併，收購，聯盟
• 法規情勢
• 主要的發展
• PEST分析

第4章 全球抗瘧疾藥市場-冠狀病毒(COVID-19)大流行病的影響

• 經濟影響
• COVID-19流行病學
• 需求與供給的影響

第5章 抗瘧疾藥的全球市場:各類藥物，2018-2030年

• 胺基[口奎][口林]
• [口奎][口林]甲醇(4-[口奎][口林]甲醇)
• 奎寧皮生物鹼
• 雙胍
• 磺胺類藥物及磺酸鹽
• 其他

第6章 抗瘧疾藥的全球市場:各給藥途徑，2018年～2030年

• 口服
• 注射

第7章 抗瘧疾藥的全球市場:各流通管道，2018年～2030年

• 醫院藥局
• 零售藥局
• 線上藥局

第8章 抗瘧疾藥的全球市場:各地區，2018年～2030年

• 北美
• 美國
• 加拿大
• 南美
• 巴西
• 墨西哥
• 阿根廷
• 其他南美國家
• 歐洲
• 德國
• 英國
• 法國
• 義大利
• 西班牙
• 俄羅斯
• 其他歐洲
• 亞太地區
• 中國
• 印度
• 日本
• 澳洲
• 韓國
• ASEAN
• 其他的亞太地區各國
• 中東
• GCC
• 以色列
• 其他中東
• 非洲
• 南非
• 中非
• 北非

第9章 競爭情形

• 企業簡介
  • Ipca Laboratories Ltd.
  • Zydus Group
  • Merck KGaA
  • Pfizer Inc.
  • GSK plc.
  • Cipla Inc.
  • Sun Pharmaceutical Industries Ltd.
  • Novartis AG
  • Alvizia Health Care
  • Bayer AG
  • F. Hoffmann-La Roche Ltd

第10章 章節

• 參考文獻
• 調查手法

Plasmodium parasites, a protozoan parasite, are the cause of the widespread infectious disease malaria. A parasite enters the body through the bite of an infected female Anopheles mosquito, which then travels to the liver, where the parasite is produced. Human malaria are generally caused by five types of plasmodium parasites, including P. falciparum, P. malariae, P. ovale, P. vivax, and P.knowlesi. The most dangerous parasite species among these are P. falciparum and P. vivax, which are also the ones responsible for the majority of malaria deaths. Antimalarial drugs are used for the treatment and prevention of malaria infection. Most antimalarial drugs target the erythrocytic stage of malaria infection, which is the phase of infection that causes symptomatic illness. Early diagnosis and efficient treatment are crucial measures to control malaria. Different types of drugs such as quinine, chloroquine, mefloquine, proguanil, primaquine, and others are used in the treatment of malaria. Moreover, some combination drugs such as Pyrimethamine & sulfadoxine, Artemether & lumefantrine, and others are also prescribed for treating the disease.

Market Dynamics

The ongoing research and development for malarial treatment is expected to fuel growth of the market in the forecast period. Various drugs are undergoing the clinical trial for the malarial treatment, which is also expected to drive the market during the forecast period. Moreover, various pharmaceutical companies are actively participating in research and development activities, in order to develop novel drug entity for treatment of malaria. For instance, in November 2022, Novartis AG, a multinational pharmaceutical corporation and Medicines for Malaria Venture (MMV), a product development partnership in the field of antimalarial drug research and development announced decision to move to Phase 3 study for novel non-artemisinin combination to treat uncomplicated malaria. This novel combination also contains an optimized formulation of lumefantrine, which allows it to be given once daily versus the usual twice-daily administration. As the world faces emerging resistance to current malaria treatments, new medicines are needed to continue the fight toward elimination.

Key features of the study:

• This report provides in-depth analysis of the global anti-malarial drugs market, and provides market size (US$ Million) and Compound Annual Growth Rate (CAGR%) for the forecast period (2023-2030), considering 2022 as the base year
• It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
• This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
• It profiles key players in the global anti-malarial drugs market based on the following parameters-company highlights, products portfolio, key highlights, financial performance, and strategies
• Key companies covered as a part of this study are Ipca Laboratories Ltd., Zydus Group, Merck KGaA, Pfizer Inc., GSK plc., Cipla Inc., Sun Pharmaceutical Industries Ltd., Novartis AG, Alvizia Health Care, Bayer AG, and F. Hoffmann-La Roche Ltd.
• Insights from this report will allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
• Global anti-malarial drugs market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
• Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global anti-malarial drugs market

Detailed Segmentation:

• Global Anti-malarial Drugs Market, By Drug Class:
  • Aminoquinolines
  • Quinoline-methanol (4-quinolinemethanols)
  • Cinchona Alkaloids
  • Biguanides
  • Sulfonamides and sulfones
  • Others
• Global Anti-malarial Drugs Market By Route of Administration:
  • Oral
  • Injectable
• Global Anti-malarial Drugs Market By Distribution Channel:
  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies
• Global Anti-malarial Drugs Market, By Region:
  • North America
    • By Country:
  • U.S.
  • Canada
  • Latin America
    • By Country:
  • Brazil
  • Mexico
  • Argentina
  • Rest of Latin America
  • Europe
    • By Country:
  • Germany
  • U.K.
  • France
  • Italy
  • Spain
  • Russia
  • Rest of Europe
  • Asia Pacific
    • By Country
  • China
  • India
  • Japan
  • Australia
  • South Korea
  • ASEAN
  • Rest of Asia Pacific
  • Middle East
    • By Country:
  • GCC
  • Israel
  • Rest of Middle East
  • Africa
    • By Country/Region:
  • South Africa
  • Central Africa
  • North Africa
• Company Profiles
  • Ipca Laboratories Ltd.*
    • Company Highlights
    • Products Portfolio
    • Key Highlights
    • Financial Performance
    • Strategies
  • Zydus Group
  • Merck KGaA
  • Pfizer Inc.
  • GSK plc.
  • Cipla Inc.
  • Sun Pharmaceutical Industries Ltd.
  • Novartis AG
  • Alvizia Health Care
  • Bayer AG
  • F.Hoffmann-La Roche Ltd

"*" marked represents similar segmentation in other categories in the respective section

Table of Contents

1. Research Objective and Assumption

• Research Objectives
• Assumptions
• Abbreviations

2. Market Purview

• Report Description
  • Market Definition and Scope
• Executive Summary
  • Market Snippet, By Drug Class
  • Market Snippet, By Route of Administration
  • Market Snippet, By Distribution Channel
  • Market Snippet, By Region
  • Coherent Opportunity Map (COM)

3. Market Dynamics, Regulations, and Trends Analysis

• Market Dynamics
  • Drivers
  • Restraints
  • Market Opportunities
• Impact Analysis
• Recent Product Launches
• Epidemiology
• Merger, Acquisition, and Collaborations
• Regulatory Scenario
• Key Developments
• PEST Analysis

4. Global Anti-malarial Drugs Market- Impact of Coronavirus (Covid-19) Pandemic

• Economic Impact
• COVID-19 Epidemiology
• Impact on Supply and Demand

5. Global Anti-malarial Drugs Market, By Drug Class, 2018-2030 (US$ Mn)

• Introduction
  • Market Share Analysis, 2023 and 2030(%)
  • Y-o-Y Growth Analysis, 2018-2030
  • Segment Trends
• Aminoquinolines
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Mn)
• Quinoline-methanol (4-quinolinemethanols)
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Mn)
• Cinchona Alkaloids
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Mn)
• Biguanides
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Mn)
• Sulfonamides and sulfones
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Mn)
• Others
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Mn)

6. Global Anti-malarial Drugs Market, By Route of Administration, 2018-2030 (US$ Mn)

• Introduction
  • Market Share Analysis, 2023 and 2030(%)
  • Y-o-Y Growth Analysis, 2018-2030
  • Segment Trends
• Oral
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Mn)
• Injectable
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Mn)

7. Global Anti-malarial Drugs Market, By Distribution Channel, 2018-2030 (US$ Mn)

• Introduction
  • Market Share Analysis, 2023 and 2030(%)
  • Y-o-Y Growth Analysis, 2018 - 2030
  • Segment Trends
• Hospital Pharmacies
  • Introduction
  • Market Size, Volume and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Mn)
• Retail Pharmacies
  • Introduction
  • Market Size, Volume and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Mn)
• Online Pharmacies
  • Introduction
  • Market Size, Volume and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Mn)

8. Global Anti-malarial Drugs Market, By Region, 2018-2030, (US$ Mn)

• Introduction
  • Market Share Analysis, By Region, 2023 and 2030(%)
  • Y-o-Y Growth Analysis, For Regions, 2018-2030
• North America
  • Market Size and Forecast, By Drug Class, 2018-2030, (US$ Mn)
  • Market Size and Forecast, By Route of Administration, 2018-2030, (US$ Mn)
  • Market Size and Forecast, By Distribution Channel, 2018-2030, (US$ Mn)
  • Market Size and Forecast, By Country, 2018-2030, (US$ Mn)
• U.S.
• Canada
• Latin America
  • Market Size and Forecast, By Drug Class, 2018-2030, (US$ Mn)
  • Market Size and Forecast, By Route of Administration, 2018-2030, (US$ Mn)
  • Market Size and Forecast, By Distribution Channel, 2018-2030, (US$ Mn)
  • Market Size and Forecast, By Country, 2018-2030, (US$ Mn)
• Brazil
• Mexico
• Argentina
• Rest of Latin America
• Europe
  • Market Size and Forecast, By Drug Class, 2018-2030, (US$ Mn)
  • Market Size and Forecast, By Route of Administration, 2018-2030, (US$ Mn)
  • Market Size and Forecast, By Distribution Channel, 2018-2030, (US$ Mn)
  • Market Size and Forecast, By Country, 2018-2030, (US$ Mn)
• Germany
• U.K.
• France
• Italy
• Spain
• Russia
• Rest of Europe
• Asia Pacific
  • Market Size and Forecast, By Drug Class, 2018-2030, (US$ Mn)
  • Market Size and Forecast, By Route of Administration, 2018-2030, (US$ Mn)
  • Market Size and Forecast, By Distribution Channel, 2018-2030, (US$ Mn)
  • Market Size and Forecast, By Country, 2018-2030, (US$ Mn)
• China
• India
• Japan
• Australia
• South Korea
• ASEAN
• Rest of APAC
• Middle East
  • Market Size and Forecast, By Drug Class, 2018-2030, (US$ Mn)
  • Market Size and Forecast, By Route of Administration, 2018-2030, (US$ Mn)
  • Market Size and Forecast, By Distribution Channel, 2018-2030, (US$ Mn)
  • Market Size and Forecast, By Country, 2018-2030, (US$ Mn)
• GCC
• Israel
• Rest of Middle East
• Africa
  • Market Size and Forecast, By Drug Class, 2018-2030, (US$ Mn)
  • Market Size and Forecast, By Route of Administration, 2018-2030, (US$ Mn)
  • Market Size and Forecast, By Distribution Channel, 2018-2030, (US$ Mn)
  • Market Size and Forecast, By Country, 2018-2030, (US$ Mn)
• South Africa
• Central Africa
• North Africa

9. Competitive Landscape

• Company Profiles
  • Ipca Laboratories Ltd.
• Company Overview
• Product Portfolio
• Key Developments
• Financial Performance
• Strategies
  • Zydus Group
• Company Overview
• Product Portfolio
• Key Developments
• Financial Performance
• Strategies
  • Merck KGaA
• Company Overview
• Product Portfolio
• Key Developments
• Financial Performance
• Strategies
  • Pfizer Inc.
• Company Overview
• Product Portfolio
• Key Developments
• Financial Performance
• Strategies
  • GSK plc.
• Company Overview
• Product Portfolio
• Key Developments
• Financial Performance
• Strategies
  • Cipla Inc.
• Company Overview
• Product Portfolio
• Key Highlights
• Financial Overview
• Strategies
  • Sun Pharmaceutical Industries Ltd.
• Company Overview
• Product Portfolio
• Key Highlights
• Financial Overview
• Strategies
  • Novartis AG
• Company Overview
• Product Portfolio
• Key Highlights
• Financial Overview
• Strategies
  • Alvizia Health Care
• Company Overview
• Product Portfolio
• Key Highlights
• Financial Overview
• Strategies
  • Bayer AG
• Company Overview
• Product Portfolio
• Key Highlights
• Financial Overview
• Strategies
  • F. Hoffmann-La Roche Ltd
• Company Overview
• Product Portfolio
• Key Highlights
• Financial Overview
• Strategies

10. Section

• References
• Research Methodology
• About us and Sales Contact